Trofinetide successful in Phase 2 trial in Fragile X
Filed with ASX · · 6 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- US$3m increase to US Army grant and INTREPID outlook update
- Share Purchase Plan offer documents
- Shareholder Update
- Shareholders provide further support for Rett syndrome
- Results in Fragile X Model with NNZ 2591
Later from Neuren Pharmaceuticals
- Appendix 4E and Financial Report 31 December 2015
- Neuren 2011 Preliminary Final Report
- Neuren Completes Phase II trial Cohort 2
- Neuren to proceed with oral NNZ2566 trial
- Rett Syndrome pre-IND meeting held with FDA
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals